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The introduction of radiation therapy (RT) with concurrent temozolomide (TMZ) chemotherapy
resulted in a major shift in the treatment of adult patients with glioblastoma. The EORTC-NCIC trial
(the Stupp trial) confirmed significant improvement in overall survival and set the standard of care
as 60 Gy in 30 fractions of RT with TMZ daily, followed by 6 months of adjuvant TMZ (1). Further,
for the first time, the field of neuro-oncology realized patients with glioblastoma who were achieving
longer-term survival, with nearly 40% alive at 2 years, and nearly 10% alive at 5 years (2).
Unfortunately, these successes have not translated into gains for elderly patients with glioblastoma. The EORTC-NCIC data offer little direction regarding best practice for the treatment of elderly
patients with glioblastoma, as only a minority of patients enrolled in the Stupp trial were older than
age 65, and patients older than 70 were excluded. Further, exploratory analyses of the EORTCNCIC data suggest that increasing age attenuates the benefit of addition of TMZ to glioblastoma
therapy, with less survival benefit among patients 65–70 years of age [hazard ratio for death, 0.78;
95% confidence interval (CI), 0.50–1.24; P = 0.29] than among younger patients (3). Meanwhile, the
incidence of glioblastoma in the elderly population has been rising (4), bringing with it a growing
need to delineate a standard of care for elderly patients.
Anecdotal evidence and previous trial data offered good reason for these patients to have been
excluded from the Stupp trial. Many elderly individuals simply cannot tolerate standard RT, let alone
combined therapy (5). As it is, the significant biological and functional heterogeneity of this cohort
of glioblastoma patients [“not every eighty year old is an eighty year old” (6)] and the many iterations
of therapy available their treatment, has resulted in a diverse approach to the care of glioblastoma in
elderly patients, as observed in an analysis captured in the SEER registry (7). Defining the standard
of care in elderly patients with glioblastoma has been of major interest, but has remained to now an
unanswered question.
That treating elderly patients with glioblastoma is appropriate was in itself a question not so long
ago. The answer to this question was elucidated by Keime-Guibert and colleagues, who in 2007
published a randomized controlled trial of 85 patients with a Karnofsky performance score of 70
or greater comparing supportive treatment alone to RT (50.4 Gy in 28 fractions) plus supportive
care for glioblastoma patients over 70 years of age (the ANOCEF trial) (8). The study was stopped
at the first interim analysis due to the finding that survival in the RT plus supportive care group was
superior to supportive care alone. Median overall survival for patients who received support care
plus radiotherapy was 6.7 months, compared to 3.9 months in patients treated with supportive care
alone. Importantly, the study found that the survival benefit offered by RT to elderly patients did not
come at the cost of health-related quality of life.
The options for therapy in this population expanded with the 2012 study from the Nordic Brain
Tumor Clinical Study Group (the Nordic trial) (9). Nordic randomized 342 patients over 65 years
of age with a good performance status (ECOG 0-2) to three single-modality treatment arms:
(1) standard-dose TMZ; (2) standard RT (60 Gy in 30 fractions); or (3) hypofractionated RT (34 Gy in
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10 fractions). 291 patients underwent treatment with a primary
endpoint of overall survival and secondary endpoints of healthrelated quality of life and safety. Patients deemed eligible for
chemoradiation were excluded. The median overall survival was
significantly longer in patients treated with TMZ (8.3 months)
or hypofractionated RT (7.5 months) compared to those who
received standard RT (6.0 months). O6-methylguanine–DNA
methyltransferase (MGMT) promoter methylation was associated with significantly higher survival rates in patients treated
with TMZ (9.7 months vs. 6.8 months), but had no effect on
survival in patients treated with RT. No difference in survival was
found in patients with an unmethylated MGMT promoter treated
with RT or single-agent TMZ (7.0 vs. 6.8 months). Patients in
the TMZ group generally reported better quality of life than did
patients in the RT groups, but the ratings for global health status
were equal.
Perry and colleagues from the CCTG/EORTC Trial Investigators
Intergroup have now brought us one step closer to an answer. In
CCTG CE.6/EORTC 26062-22061/TROG patients 65 years of
age or older with newly diagnosed glioblastoma were randomly
assigned to receive either RT alone (40 Gy in 15 fractions) or
RT with concomitant and adjuvant TMZ (10). 562 patients were
randomized. The median age was 73 years (range, 65–90). Patients
deemed by their physicians to be suitable to receive conventional
RT were excluded. Eligible patients had an ECOG performance
status of 0, 1, or 2 and were receiving glucocorticoids at a stable or
decreasing dose. Quality-of-life assessment was performed weekly
during RT, then 1 week after the last day of RT, and then every
3 months until disease progression, using the EORTC Qualityof-Life Questionnaire-Core 30 (QLQ-C30) and the EORTC brain
module (QLQ-BN20). Progressive disease was defined as objective radiographic progression. If brain imaging could not be performed, symptomatic progression was used to define progression.
The primary end point was overall survival, measured from the
date of randomization until death or censoring at the last day that
the patient was known to be alive. Progression-free survival was
measured from the date of randomization until disease progression or death (if no progression was reported) or until the last
evaluation date.
All 562 randomly assigned patients (281 in each group)
were included in the intention-to-treat analysis. Among the 503
samples examined centrally, glioblastoma was confirmed in 480
(95.4%), high-grade glioma in 15 (3.0%), diffuse glioma lacking
high-grade features in 5 (1.0%), and anaplastic oligodendroglioma
in 3 (0.6%). Immunohistochemical staining for the IDH1 R132H
mutation was positive in only 4 of the 481 specimens deemed
suitable for analysis. Treatment adherence was high. The median
duration of concomitant TMZ was 21 days, as planned. The
median number of adjuvant cycles delivered was five. A similar
percentage of patients in the two groups (197 of 493 patients,
40.0%) received other anticancer therapies at disease progression.
RT plus TMZ was associated with more adverse events than RT
alone, with a higher rate of grade 3 or 4 events, but no difference
between the two groups in terms of serious adverse events leading
to death.
Baseline factors that correlated with overall survival included
the extent of resection and MMSE score: patients with biopsy
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only had shorter survival than those with partial or complete
resection. In Cox regression modeling with adjustment for baseline factors, RT plus TMZ remained significantly better than RT
alone with respect to overall survival, with an estimated hazard
ratio of 0.67 (95% CI, 0.56–0.80; P < 0.001). The median overall
survival was longer with RT plus TMZ than with RT alone (9.3
vs. 7.6 months; hazard ratio for death, 0.67), as was the median
progression-free survival (5.3 vs. 3.9 months; hazard ratio for
disease progression or death, 0.50). Among 165 patients with
methylated MGMT status, the median overall survival was
13.5 months with RT plus TMZ and 7.7 months with RT alone
(hazard ratio for death, 0.53). Interestingly, even patients with
unmethylated MGMT status benefited from the addition of
chemotherapy: among 189 patients with unmethylated MGMT
status, the median overall survival was 10.0 months with RT
plus TMZ and 7.9 months with RT alone (hazard ratio for death,
0.75). Measures of quality of life showed no significant difference
in the two trial groups. Further, exploratory analyses of overall
survival at 12, 18, and 24 months suggested that the benefit of
radiation and concurrent and adjuvant chemotherapy on OS
is long standing. Unfortunately, combined therapy in elderly
patients does not appear to garner long-term survivorship as it
does in younger patients: the CE.6 trial cohort had no survivors
beyond 3 years.
The CE.6 trial data, while methodologically sound, were
at times scientifically difficult to make sense of. Patients with
unmethylated MGMT derived a clinically meaningful if not
statistically significant (P = 0.55) overall survival advantage
from the addition of TMZ to RT. It is difficult to make sense
of this outcome biologically, and difficult to reconcile it with
findings from the Stupp trial, in which benefit from combined
therapy was more pronouncedly realized in MGMT methylated patients. This discrepancy could be an artifact of the
assay used in CE.6 to determine MGMT methylation status
(real-time methylation-specific PCR), which risks “misclassifying” patients with lower levels of MGMT methylation
as unmethylated (11). Further, patients 65–70 years of age
derived less benefit from the addition of TMZ than those
71–75 years of age or 76 years of age or older. The CE.6 trial
investigators adroitly suggest that this seeming discrepancy
could be an indirect result of excluding younger elderly
patients who were deemed to be eligible for standard (Stupp
protocol) combined chemoradiation; in other words, the
CE.6 trial may have been biased to include more robust older
elderly patients, while accruing less medically fit younger
elderly patients.
Many questions remain to be asked. For example, should
medically eligible older patients receive standard (Stupp protocol) combined chemoradiation? And if so, what criteria should
be used to determine which elderly patients are medically eligible
for standard therapy? Conversely, are there elderly patients who
should be treated with palliative RT alone, or some patients who
would be better served by treatment with TMZ monotherapy?
Finally, which assay should be used to determine MGMT methylation status? These questions will require future work. For now,
Perry and colleagues should be congratulated for clarifying the
path forward.
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